Colonoscopy proves cost-effective in young patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

Conducting colonoscopies for people in their mid 50s can save money, according to research presented at the 2008 American College of Gastroenterology meeting in Orlando, Fla. The savings averages $2 for every dollar spent, the study found.

Conducting colonoscopies for people in their mid 50s can save money, according to research presented at the 2008 American College of Gastroenterology meeting in Orlando, Fla. The savings averages $2 for every dollar spent, the study found.

Jianjun Li, MD, and colleagues at New York’s Maimonides Medical Center reported results of a study involving free screening colonoscopies for 248 consecutive patients (average age of 55). Nearly 45% had polyps. Follow-up testing demonstrated that fi ve individuals had early-stage colon cancer, and 22 had polyps larger than 1 cm.

The screening program cost $390,000. If colon cancer treatment had been delayed until the Medicare eligibility age of 65, the cost would have been nearly $1.3 million, Dr. Li said. If these patients had not been screened, their disease would have progressed undetected, said Judy Yee, MD, vice chair of radiology at the University of California, San Francisco. As people grow older, their risk of developing polyps increases, she said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content